Skip to Main Content

The market for biotechnology stocks is ghastly, but ARCH Venture Partners, one of the largest and most prolific investors in early-stage biotech startups, is doubling down, raising $2.975 billion to invest in high-risk, high-reward startups developing new therapies and diagnostics.

Robert Nelsen, ARCH’s co-founder and managing director, said the goal was to take advantage of a “massive and accelerating wave of innovation that is really going to change health care for the better.”


“There’s a lot of great companies we want to start, and a lot of great opportunities that we’re seeing percolate up out of academic institutions,” said Kristina Burow, another of the firm’s managing directors. Some of those opportunities, she said, require a level of investment that is “made easier by a fund of this size.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.